Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus

LESS IS MORE
Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus
Justin W. Timbie, PhD; Rodney A. Hayward, MD; Sandeep Vijan, MD
Arch Intern Med. 2010;170(12):1037-1044.

Background Lowering low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) in patients with diabetes mellitus (DM) can significantly reduce the risk of cardiovascular disease (CVD). However, to our knowledge, previous studies have not assessed variability in both the benefit and harm from pursuing LDL-C and BP target levels.

Methods Our sample comprised individuals 30 to 75 years old with DM participating in the National Health and Nutrition Examination Survey III. We used Monte Carlo methods to simulate a treat-to-target strategy, in which patients underwent treatment intensification with the goal of achieving LDL-C and BP target levels of 100 mg/dL and 130/80 mm Hg, respectively. Patients received up to 5 titrations of statin therapy and 8 titrations of antihypertensive therapy. Treatment adverse effects and polypharmacy risks and burdens were incorporated using disutilities. Health outcomes were simulated using a Markov model.

Results Treating to targets resulted in gains of 1.50 (for LDL-C) and 1.35 (for BP) quality-adjusted life-years (QALYs) of lifetime treatment-related benefit, which declined to 1.42 and 1.16 QALYs after accounting for treatment-related harms. Most of the total benefit was limited to the first few steps of medication intensification or to tight control for a limited group of very high-risk patients. However, because of treatment-related disutility, intensifying beyond the first step (LDL-C) or third step (BP) resulted in either limited benefit or net harm for patients with below-average risk.

Conclusion The benefits and harms from aggressive risk factor modification vary widely across the US population of individuals with DM, depending on a patient's underlying CVD risk, suggesting that a personalized approach could maximize a patient's net benefit from treatment.


Author Affiliations: RAND Health, RAND Corp, Arlington, Virginia (Dr Timbie), Department of Internal Medicine and the Robert Wood Johnson Clinical Scholars Program, University of Michigan, Ann Arbor (Drs Hayward and Vijan), and Veterans Affairs, Ann Arbor Healthcare System (Drs Hayward and Vijan), Ann Arbor.


open here please:
Arch Intern Med. 2010;170(12):1037-1044.
http://archinte.ama-assn.org/cgi/content/abstract/170/12/1037?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=timbie&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Archives of Internal Medicine
http://archinte.ama-assn.org/

RAND Corporation
http://www.rand.org/